Pancreatic Cancer Research

ResearcherAichi Medical UniversityActive in the last 2 years

Akinobu Taketomi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5238-3678; OpenAlex author ID A5086522106. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 4 papers · 2019: none · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers

Papers 11

  1. Impact of the COVID-19 pandemic on short-term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Cl… Co-author DOI 10.1002/ags3.12798↗
  2. A Circulating Panel of circRNA Biomarkers for the Noninvasive and Early Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2023.09.050↗
  3. HOPS-R01 phase II trial evaluating neoadjuvant S-1 therapy for resectable pancreatic adenocarcinoma. Last author DOI 10.1038/s41598-022-14094-0↗
  4. Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreat… Last author DOI 10.1007/s10637-021-01118-1↗
  5. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive panc… Last author DOI 10.1186/s12885-020-07722-3↗
  6. Pancreaticoduodenectomy with Preservation of Collateral Circulation or Revascularization for Biliary Pancreatic Cancer with Celiac Axis Occlusion: A Report of … Last author DOI 10.12659/ajcr.908516↗
  7. The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in … Last author DOI 10.18632/oncotarget.26117↗
  8. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy. Last author DOI 10.21873/invivo.11362↗
  9. Curative resection of pancreatic ductal adenocarcinoma developing in the remnant pancreas 13 years after distal pancreatectomy for intraductal papillary mucino… Last author DOI 10.3892/mco.2018.1556↗
  10. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy. Last author DOI 10.1186/1471-2407-14-687↗
  11. Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer cells by a nuclear factor-κB inhibitor, (-)-DHMEQ. Co-author DOI 10.3727/096504014x14024160459249↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirofumi Kamachi · 8 shared papers, 2014–2022 · strength 0.73
  2. Tatsuzo Mizukami · 4 shared papers, 2014–2021 · strength 0.40
  3. Fumihiko Matsuzawa · 3 shared papers, 2018–2021 · strength 0.36
  4. Takahiro Einama · 3 shared papers, 2018–2021 · strength 0.28
  5. Yuki Fujii · 2 shared papers, 2021 · strength 0.28
  6. John S. Bolton · 1 shared paper, 2024 · strength 0.20
  7. Caiming Xu · 1 shared paper, 2024 · strength 0.20
  8. Eunsung Jun · 1 shared paper, 2024 · strength 0.20
  9. Guixin Zhang · 1 shared paper, 2024 · strength 0.20
  10. Dong Shang · 1 shared paper, 2024 · strength 0.20
  11. Erkut Hasan Borazanci · 1 shared paper, 2024 · strength 0.20
  12. Ajay Goel · 1 shared paper, 2024 · strength 0.20
  13. Song Cheol Kim · 1 shared paper, 2024 · strength 0.20
  14. Daniel D. Von Hoff · 1 shared paper, 2024 · strength 0.20
  15. Masaki Mori · 1 shared paper, 2024 · strength 0.18
  16. Yasuyuki Seto · 1 shared paper, 2024 · strength 0.18
  17. Hideki Ueno · 1 shared paper, 2024 · strength 0.18
  18. Yutaka Nakano · 1 shared paper, 2024 · strength 0.18
  19. Yusuke Takemura · 1 shared paper, 2024 · strength 0.18
  20. Yuko Kitagawa · 1 shared paper, 2024 · strength 0.18
  21. Kazuhiro Hanazaki · 1 shared paper, 2024 · strength 0.18
  22. Kazuaki Shibuya · 2 shared papers, 2018 · strength 0.15
  23. Junpei Sasajima · 1 shared paper, 2022 · strength 0.10
  24. Yohei Kitano · 1 shared paper, 2022 · strength 0.10
  25. Tsuyoshi Hayashi · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.